Firefly Neuroscience, Inc. (NASDAQ: AIFF) 2025 Annual Report – Key Investor Highlights

Executive Summary

Firefly Neuroscience, Inc. (“Firefly” or the “Company”) has released its Form 10-K annual report for the fiscal year ended December 31, 2025. The filing provides a comprehensive overview of Firefly’s financial position, recent strategic developments, capital structure, and potential risk factors that investors should carefully consider. This report contains several items that could be material to the valuation of Firefly’s shares, including details on the Company’s recent merger, share structure, capital raises, and product positioning.

Key Points and Price-Sensitive Information

1. Corporate Identity and Strategic Transformation

• Reverse Merger: During the reporting period, Firefly Neuroscience, Inc. completed a reverse merger with WaveDancer, Inc., resulting in the renaming of the combined entity to Firefly Neuroscience, Inc. This transformative event could have significant implications for the Company’s strategic direction, leadership, and operational focus.
• Product Portfolio: Firefly’s lead product is the FDA 510(k)-cleared Brain Network Analytics software platform (“Firefly System”), targeting the neuroscience sector with advanced AI-driven EEG analytics.

2. Capital Structure and Share Information

• Common Stock: As of March 25, 2026, Firefly had 14,793,075 shares of common stock outstanding. The par value is \$0.0001 per share.
• Public Float: As of June 30, 2025, the aggregate market value of shares held by non-affiliates was approximately \$31.3 million, based on Nasdaq Capital Market closing prices.
• Preferred Stock: The Company has authorized 1,000,000 shares of preferred stock, none of which were outstanding as of December 31, 2025.
• Recent Financings: Firefly conducted a Series C Financing between October 2023 and June 2024, issuing Series C Preferred Stock and Series C Warrants in private placements. Additionally, a July 2024 Securities Purchase Agreement led to the issuance of common stock, pre-funded warrants, and warrants to PIPE investors.
• Warrants: The Company issued warrants to purchase up to 823,530 shares of common stock at \$0.71 per share and pre-funded warrants to purchase up to 1,124 shares at \$0.0001 per share, in addition to Series C Warrants and Broker Warrants.
• Potential Dilution: The presence of outstanding warrants, pre-funded warrants, and rights under recent private placements could introduce significant dilution risk for current shareholders if exercised.

3. Nasdaq Listing and Compliance

• Nasdaq Listing: Firefly’s common stock trades on the Nasdaq Capital Market under the ticker “AIFF”. The Company highlights the risk of possible delisting or the failure to develop an active trading market, which could impact liquidity and valuation.

4. Financial Reporting and Compliance

• Filing Status: Firefly is a non-accelerated filer and a smaller reporting company. The Company has not filed a report from an independent auditor on the effectiveness of its internal controls over financial reporting, as permitted by its status.
• No Restatements or Shell Company Status: The Company did not correct any errors requiring restatement or recovery analysis of executive incentive compensation. Firefly is not a shell company.

5. Recent Business Acquisition

• Acquisition of Evoke Neuroscience, Inc.: Firefly completed the acquisition of Evoke Neuroscience, Inc., which may provide additional intellectual property, technology, or market access. The transaction included contingent consideration in the form of earn-out shares.

6. Cybersecurity and Risk Management

• Cybersecurity Oversight: Management is primarily responsible for assessing, monitoring, and managing cybersecurity risks. The Company reports compliance with industry-standard measures and regular employee training; there have been no material cybersecurity incidents affecting the Company.

7. Forward-Looking Statements and Risks

• The Company’s report includes numerous forward-looking statements regarding market volatility, funding needs, dilution risk, legal proceedings, Nasdaq compliance, and the potential impact of its strategic shift and merger. These factors could materially affect future performance and share value.
• Key risks highlighted include: market volatility, dilution from new equity, delisting risk, litigation exposure, and the uncertain impact of the Company’s changed business strategy and focus.

What Investors Should Watch For

1. Shareholder Dilution: The large number of outstanding and potentially issuable shares from warrants, pre-funded warrants, and private placements could dilute existing shareholders if exercised.
2. Execution on Strategic Shift: The success of the recently completed merger and the integration of new technologies and personnel are critical for value creation.
3. Nasdaq Compliance: Any risk of delisting or lack of trading liquidity could negatively impact share price.
4. Capital and Cash Position: The Company’s ability to secure additional funding to support operations is a key risk.
5. Product Commercialization: The regulatory-cleared Firefly System’s market acceptance and commercial success will drive future growth.
6. Litigation and Cybersecurity: While no adverse events are noted, any future litigation or cybersecurity incident could materially impact operations.

Conclusion

Firefly Neuroscience, Inc. is in a period of significant transition, having completed a transformative merger and several capital raises. Investors should be vigilant regarding the Company’s ability to leverage its expanded product portfolio, manage dilution, comply with Nasdaq requirements, and secure new growth opportunities. These factors, along with the risks of market volatility and ongoing integration challenges, could all materially affect Firefly’s share price in the coming quarters.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information is based on the Company’s 2025 SEC Form 10-K filing and other publicly available data. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The author and publisher accept no liability for any actions taken based on the information contained herein.

View FIREFLY NEUROSCIENCE, INC. Historical chart here